Home » Newsletters » BioWorld Asia

BioWorld Asia

Sep. 13, 2000

View Archived Issues

PowderJect To Pay US$79.2M For Celltech's Vaccine Arm

Cureon To Develop Therapeutic Applications Of LNA Platform

Cell Therapy More Promising After Stem Cell Breakthrough

Peptor Diabetes Drug Looks Promising At Phase II Interim

European Parliament Condemns British Decision To Allow Cloning

Antisoma Harnesses Cyanide, Antibodies For Cancer Therapy

Medarex To Create Antibodies For OGS Proteomics Targets

IsoTis Gearing Up For Trials, October Stock Market Float

ExonHit Raises US$12M, Prepares For IPO In 2001

Biotie Targets Inflammation Protein With Dual Activity

Amrad Advances Clinical Slate, Including HBV, Pain Therapies

Other News To Note

Bionomics Seeking Partners For Cancer, Epilepsy Genes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...